| Nov 7 |
Q32 Bio GAAP EPS of -$1.46
|
| Nov 7 |
Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update
|
| Nov 5 |
Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference
|
| Oct 14 |
Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024
|
| Aug 29 |
Q32 Bio to Participate in Upcoming September Investor Conferences
|
| Aug 29 |
Q32 Bio: High-Risk, High-Reward With Bempikibart And ADX-097
|
| Aug 8 |
Q32 Bio GAAP EPS of -$1.42
|
| Jul 31 |
Russell 2000 rise: Top 5 best, worst performers during July's rally in small-cap stocks
|
| Jul 9 |
Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis
|
| Jul 1 |
Q32 Bio to join Russell 3000 Index
|
